Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation

Efsubaglutide Alfa 1 mg provided clinically meaningful glucose lowering with good tolerability but without significant weight loss. These results support a lower-dose strategy for elderly or frail patients, those with low BMI, or individuals sensitive to gastrointestinal effects, and as a possible lead-in step before escalation. Confirmatory trials are warranted to establish long-term outcomes.